TY - JOUR
T1 - The HBV Drugs Work
T2 - Now What?
AU - Pruett, Timothy L.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Chemotherapeutic agents for Hepatitis B virus (HBV) suppression work, but only when administered to the patient. They do not appear to promote durable, long-term immunological control. After 3 years of effective anti-HBV therapy, a small percentage of patients maintained good control, manifest by controlled serum liver enzymes, low-level HBV-DNA, and controlled HBsAg concentrations. However, this did not occur in the majority of patients. We need a better understanding of the defects in HBV immunity and how to induce effective reconstitution that will maintain viral suppression, albeit either through innate or adaptive immunity.
AB - Chemotherapeutic agents for Hepatitis B virus (HBV) suppression work, but only when administered to the patient. They do not appear to promote durable, long-term immunological control. After 3 years of effective anti-HBV therapy, a small percentage of patients maintained good control, manifest by controlled serum liver enzymes, low-level HBV-DNA, and controlled HBsAg concentrations. However, this did not occur in the majority of patients. We need a better understanding of the defects in HBV immunity and how to induce effective reconstitution that will maintain viral suppression, albeit either through innate or adaptive immunity.
UR - http://www.scopus.com/inward/record.url?scp=84984920220&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84984920220&partnerID=8YFLogxK
U2 - 10.1038/ajg.2016.279
DO - 10.1038/ajg.2016.279
M3 - Short survey
C2 - 27580778
AN - SCOPUS:84984920220
SN - 0002-9270
VL - 111
SP - 1295
EP - 1296
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 9
ER -
